Tositumomab
Tositumomab is a murine anti-CD20 monoclonal antibody used as part of radioimmunotherapy (Bexxar system), where it is combined with iodine-131-labeled tositumomab to deliver targeted radiation to CD20-positive B-cell non-Hodgkin lymphoma cells. The cold antibody component saturates non-tumor CD20 sites to improve biodistribution of the radiolabeled antibody. It was used for relapsed or refractory follicular lymphoma but was withdrawn from the market due to commercial factors.
Aires thérapeutiques
Mécanisme d'action
As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.
HBD / HBA
- / -
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Foire aux questions
Tositumomab is a murine anti-CD20 monoclonal antibody used as part of radioimmunotherapy (Bexxar system), where it is combined with iodine-131-labeled tositumomab to deliver targeted radiation to CD20-positive B-cell non-Hodgkin lymphoma cells. The cold antibody component saturates non-tumor CD20 sites to improve biodistribution of the radiolabeled antibody. It was used for relapsed or refractory follicular lymphoma but was withdrawn from the market due to commercial factors.
As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.
Yes, Tositumomab is an approved drug. It has reached clinical phase 4. It is classified as a Antibody.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201604. Open-access bioactivity database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="tositumomab"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/tositumomab/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/tositumomab/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/tositumomab/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="tositumomab"></drugfyi-drug>